



Market Round-up

V30 – 4th January, 2019

General Market News:

- **Bristol-Myers Squibb** announced it will buy Celgene in a cash and stock transaction worth \$74 billion.
[LINK](#)
- **Boston Scientific** buys **Millipede** and its mitral regurgitation device for \$325M
[LINK](#)
- New breast cancer protein discovered, which could be targeted for developing new and improved therapies.
[LINK](#)
- **Teva, Amgen** end dispute over generic **Cinacalcet HCl** tablets
[LINK](#)
- **Pfizer** and **Merck** have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of **Bavencio**, as the data did not support the study's initial hypothesis.
[LINK](#)

NCPE Drug Updates

- No Updates this week.

Drug Approvals/Filings:

- **NHS** has announced it will fund **Novartis' Afinitor (everolimus)** for patients living with Tuberous Sclerosis Complex (TSC)
[LINK](#)
- **FDA** approves **Cardiva's** new bioabsorbable vessel closure system
[LINK](#)
- **Bristol-Myers Squibb** announced that their **Sprycel** combo has received FDA approval
[LINK](#)